MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

(MENAFN - AsiaNet News) The company said the independent safety board reviewing the study saw a clear trend favoring the Annamycin combination, though there was no statistical significance. ...